Paul R. Fortin
Chercheur universitaire clinicien
Axe Maladies infectieuses et immunitaires
Maladies auto-immunes
Publications
Voir tout-
article Adams C, Carrier ME, Golberg M, Co N, Nassar EL, Kwakkenbos L, Bartlett SJ, Fortuné C, Gietzen A, Guillot G, Lawrie-Jones A, Malcarne VL, Mayes MD, Richard M, Mouthon L, Benedetti A, Thombs BD and
Health literacy among people with systemic sclerosis: a scleroderma patient-centred intervention network (SPIN) cohort cross-sectional study
Rheumatology (Oxford) 65 (10), 2026.
-
article Foddai SG, Cecchi I, Radin M, Bertolaccini L, de Andrade D, Tektonidou M, Pengo V, Lopez-Pedrera C, Paredes-Ruiz D, Belmont HM, Fortin PR, Wahl D, Branch W, Gerosa M, de Jesus G, Zhang Z, Atsumi T, Efthymiou M, Andreoli L, Rodriguez E, Petri M, Cervera R, Artim-Esen B, Quintana R, Knight JS, Willis R, Cobanoglu RK, Cohen H, Erkan D, Sciascia S
Clinical characteristics of patients with primary antiphospholipid syndrome and « single » antiphospholipid antibody: Retrospective results from the APS ACTION clinical database an…
Lupus 35 (13), 2026.
-
article Arnaud L, Monticielo OA, Piga M, Costedoat-Chalumeau N, Touma Z, Ruiz-Irastorza G, Bae SC, Bernatsky S, Bonfa E, Bottazzi F, Cervera R, Chehab G, Clarke AE, Dall'era M, Duarte-Garcia A, Espinosa G, Fortin PR, Fredi M, Gómez-Puerta JA, Izuka S, Jönsen A, Khmelinskii N, Legge A, Meisalu S, Moroni L, Orsolini G, Padjen I, Petri M, Pons-Estel G, Ramirez GA, Ramsey-Goldman R, Sciascia S, Tincani A, Triggiani M, Ugarte-Gil MF, Vinet E, Vital EM, Mosca M, Tani C and
ERN ReCONNET-SLICC-SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations (part 2)
Lancet Rheumatol 8 (10), 2026.
Projets
- Booster dose of mRNA SARS-CoV-2 vaccine vs non mRNA vaccine for people living with systemic autoimmune rhumatic diseases without adequate humoral response post standard mRNA vaccination, du 2021-12-01 au 2027-03-31
- Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases, du 2023-01-01 au 2026-12-31
- Role of megakaryocytes in Systemic Lupus Erythematosus, du 2023-04-01 au 2028-03-31
- Risk stratification and personalized therapy in lupus pregnancies, du 2022-10-01 au 2027-09-30
- The contribution of platelets and B-cells to neurolupus pathophysiology, du 2025-10-01 au 2030-09-30
- Impact of vascular injury derived exosomes on Lupus nephritis, du 2022-04-01 au 2027-03-31
- Canada research chair in Innovate Systemic Autoimmune Rheumatic Disease, du 2019-07-01 au 2026-06-30
- Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, du 2020-04-01 au 2025-03-31
- FcgRI as a potential therapeutic target in inflammatory arthritis, du 2022-01-01 au 2025-12-31
- Mitochondrial mArkers To Characterize Heterogeneity in SLE (MATCH-SLE) (Planning grant), du 2024-12-01 au 2025-02-28
- Mental Health in Individuals with Autoimmune Rheumatic Diseases During the Transition to Parenthood: A Mixed Methods Study to Identify Associated Factors and Support Needs, du 2023-04-01 au 2025-09-30
- Pilot Implementation of the Purple Butterfly: Transforming Communication and Self-Management in Lupus Care, du 2025-09-23 au 2026-03-31